Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy). Data from the phase III ASCENT-03 ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Friday announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy in patients with first-line metastatic triple-negative breast cancer ...

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda. ASCENT-04 ...

April 21 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's (MRK.N), opens new tab immunotherapy ...

Gilead Sciences plans to voluntarily withdraw U.S. accelerated approval for Trodelvy in metastatic urothelial cancer. The decision followed results from the TROPiCS-04 study, which failed to meet ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...